Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1906 to 1920 of 7682 results

  1. Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]

    In development [GID-TA10497] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment

    In development [GID-HTE10011] Expected publication date: TBC

    Health technology evaluations
    In development

  3. Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over TS ID 11891

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910

    Awaiting development [GID-TA11403] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development [GID-TA11154] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over TS ID 11892

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years TS ID 11887

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905

    Awaiting development [GID-TA11414] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg TS ID 11894

      Status ...

    Technology appraisal guidance
    Topic selection

  10. TAK-880 for managing primary immunodeficiency diseases in people hypersensitive to IgA TS ID 11883

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]

    Awaiting development [GID-TA11198] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

    Awaiting development [GID-TA11130] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Arthrosamid for symptomatic treatment of knee osteoarthritis

      Status ...

    Medical technologies guidance
    Topic selection

  14. Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642

    Awaiting development [GID-TA11308] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147

    Awaiting development [GID-TA11327] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development